ABSTRACT:
Aim of the study: The main objective of present research work is to formulate the famotidine orodispersible tablets. Famotidine is a selective H2 receptor antagonist or H2 blocker belongs to BCS Class-II and is used to treat heartburn and duodenal ulcers. Materials and methods: The Orodispersible tablets of famotidine were prepared employing different concentrations of sodium starch glycolate, Crospovidone and Croscarmellose sodium in different combinations as superdisintegrants by direct compression. Mannitol and sodium saccharine were added to microcrystalline cellulose Magnesium stearate as a diluent to improve the organoleptic qualities of the tablets. using 23 factorial design mothod was used to formulate orodispersible tablet. Prepared tablets were then subjected to different tests for tablets like Wetting time, Water absorption ratio in-vitro disintegration time, thickness, diameter, hardness, friability, weight variation, drug content, and in-vitro dissolution study were all assessed for the tablets. Design expert study was conducted to know the interaction between different superdisintegrants and to select best optimized formulation in among all formulations. Results: The tablets' good mechanical strength was indicated by the hardness and friability data. The tablets quickly dispersed in the mouth in less than 12 seconds, according to the F5 in vitro disintegration time results respectively, and 99.24% of the drug release in 15 minutes. The optimal formulations of Famotidine Orodispersible tablets for enhancing the drug's bioavailability and onset of action were determined to be F5. Conclusion: The optimized formulation showed increased drug release compared to commercially available orodispersible tablets. No changes in disintegration time, drug content and in in vitro drug release from optimized formulation on storage for 1months at 40°C ± 2°C /75% RH ± 5% RH were observed during stability studies which confirmed the stability of the optimized formulation.
Cite this article:
Pallavi P. Ahire, Yashpal M. More, Vinay R. Kothawade. Formulation, Development and Evaluation of Famotidine Orodispersible Tablets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(4):317-4. doi: 10.52711/0975-4377.2024.00049
Cite(Electronic):
Pallavi P. Ahire, Yashpal M. More, Vinay R. Kothawade. Formulation, Development and Evaluation of Famotidine Orodispersible Tablets. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(4):317-4. doi: 10.52711/0975-4377.2024.00049 Available on: https://rjpdft.com/AbstractView.aspx?PID=2024-16-4-3
REFERENCES:
1. Abhay Asthana, Swati Aggarwal, Gayti Asthana. Oral Dispersible Tablets: Novel Technology and Development, International Journal of Pharmaceutical Sciences Review and Research. 2013; 20(1): 193-199.
2. K.P.R. Chowdary, K. Ravi Shankar and B. Suchitra. Recent Research on Orodispersible Tablets – A Review. International Research Journal of Pharmaceutical and Applied Sciences. 2014; 4(1): 64-73.
3. Leon Lachman, Herber. A. Lieberman: Theory and Practice of Industrial Pharmacy. Varghese Publishing House, III rd. edition. 293
4. Herbert A. Lieberman, Leon Lachman, and Joseph B. Schwartz: Pharmaceutical Dosage Forms: Tablets. IInd edition, Volume III rd. 1-74
5. Raymond C., Rowe, Paul J., Sheskey and Sian C., Owen., Hand Book of Pharmaceutical Excipients, 4th edn., Pharmaceutical Press, London, 2003.
6. Vyomesh N. Raval, Gajanan J. Deshmukh, A. K. Seth. Oro Dispersible Tablets. Indo American Journal of Pharmaceutical Research Research. 2011: 1: 42-50
7. Lieberman HA, Lachman L. Pharmaceutical dosage forms tablets. 2nd ed. New York: Marcel Dekker. 1989; 198: 9-15
8. United States Pharmacopeia. National Formulary USP/NF18. Peckville M.D., New York: The United States Pharmacopeia Convention. 1995; 15: 133-145
9. Banker GS, Anderson NR. In: Lachman L, Lieberman HA, Kanig JL, Eds. The Theory and Practice of Industrial Pharmacy. 3rd ed. Mumbai: Varghese Publishing House. 1987; 293-399.
10. Arora P, Arora V. Orodispersible tablets: A comprehensive review. Int. J. Pharm. Sci. Res. 2013; 2(2): 270-281.
11. Furtado S. Development and Characterization of Orodispersible Tablets of Famotidine Containing a Subliming Agent. Tropical Journal of Pharmaceutical Research. 2008; 7(4): 1185-1189.
12. British Pharmacopoeia: Famotidine. Volume I and II. 2013. Ph. Eur. Monograph 1012.